Autoimmune encephalitis
Conditions
Interventions
second-line immunotherapy:None
Sponsors
Renji Hospital,Shanghai Jiaotong University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Compliance with the 2022 Chinese Expert Consensus on Autoimmune Encephalitis, with positive autoimmune encephalitis antibodies detected in cerebrospinal fluid (CSF) or serum during the acute phase. 2. Age range between 18 and 75 years. 3. Patients with newly diagnosed or recurrent autoimmune encephalitis. 4. Modified Rankin Scale (mRS) score of >=3 or no improvement in mRS after 2 weeks of first-line immunotherapy (high-dose corticosteroids, intravenous immunoglobulin [IVIg], or plasma exchange).
Exclusion criteria
Exclusion criteria: 1. Patients with infections such as human immunodeficiency virus (HIV), brain abscess, viral diseases of the central nervous system, bacterial, fungal, parasitic, or Mycobacterium tuberculosis infections, or cerebral malaria. 2. Patients diagnosed with brain tumors or non-infectious central nervous system diseases (e.g., ADEM) or those with progressively worsening neurological conditions unrelated to autoimmune encephalitis. 3. Patients with encephalopathy secondary to sepsis or systemic inflammatory response syndrome. 4. Patients who have received treatments including anti-CD19 monoclonal antibodies, anti-CD20 monoclonal antibodies, IL-6 inhibitors, complement inhibitors, FcRn antagonists, anti-B lymphocyte stimulator monoclonal antibodies, MTX, CTX, or bortezomib within the past six months. 5. Patients lacking essential clinical data. 6. Patients who are pregnant, breastfeeding, or planning to become pregnant. 7. Patients deemed unsuitable for participation in the study by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Neurological functional outcome;Relapse; | — |
Secondary
| Measure | Time frame |
|---|---|
| CASE score;Mini-Mental State Examination (MMSE);Montreal Cognitive Assessment (MoCA);Patient Health Questionnaire-9;Generalized Anxiety Disorder 7;Pittsburgh sleep quality index (PSQI);Activity of Daily Living Scale(ADL);Lymphocyte subpopulation analysis;Plasma Immunoglobulin analysis;Serum levels of complement;percentage of plasma cells;titer of autoimmune encephalitis antibody; | — |
Countries
China
Contacts
Public ContactYong Hao
Renji Hospital,Shanghai Jiaotong University School of Medicine
Outcome results
None listed